Masarova on the Latest Updates Across Myeloproliferative Neoplasms

Lucia Masarova, MD, PhD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses some of the latest updates across myeloproliferative neoplasms (MPNs).

She discusses some significant studies, including the TRANSFORM-1 and MANIFEST-2 studies (NCT04472598; NCT04603495), and emerging therapeutic approaches, like combining ruxolitinib (Jakafi) with other agents, such as pelabresib (CPI-0610) and navitoclax.

Transcription:

0:09 | We are waiting for the top-line results of the phase 3 studies of the frontline ruxolitinib and the navitoclax vs ruxolitinib and placebo, as well as the top-line results of the other combo of ruxolitinib and pelabresib vs ruxolitinib and placebo. Both of those, the TRANSFORM-1 and MANIFEST-2 study studies, are highly expected results. They are coming to see whether we can move from the monotherapy of a JAK inhibitor to the combination of arms of both of the agents. That will expand the field, hopefully, and we will see where it is going to go. [There are] excellent results for spleen control that are exciting, the symptoms will need to be worked out, so we will see where it goes.

0:53 | There are other novel molecules and other following proteasome inhibitors, very interesting data this year about other pathways…some data on the MEK pathway, so quite exciting discoveries or movements in the pathogenesis of the disease. Also, some nice transcriptomics or sequencing of the progressed chronic MPN’s to accelerated phase or blastic phase where we do not have any compounds, so hopefully, we will find something soon, so that is really exciting. And of course, the calreticulin space, that is a hot topic, to see how the monoclonal antibody that was presented at the last ASH plenary session, and now the newer one with the CD3, so the bispecific, [work], so the field is moving with huge steps.

1:46 | There are a lot of other updates or data on the smaller molecules…so we have quite the excitement this year and we will see where it takes us.